While PPARγ agonists are known to enhance insulin sensitivity and aid in managing type 2 diabetes, their clinical use is often restricted due to significant side effects, including an increased risk of heart failure, weight gain, bone fragility, edema, and cancer. The gene discussed is PPARG; the disease is heart failure.